Merck & Co. (MRK)
(Delayed Data from NYSE)
$109.77 USD
-0.41 (-0.37%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $109.53 -0.24 (-0.22%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
MRK 109.77 -0.41(-0.37%)
Will MRK be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Stock Market News for Oct 4, 2024
Merck (MRK) Dips More Than Broader Market: What You Should Know
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for MRK
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024
Buy 2 October Dogs Of The Dow And Watch 5 More
Merck KGaA (0O14) Receives a Buy from Jefferies
EU regulators reviewing safety of finasteride, dutasteride
Career on Purpose (Episode 1): Merck's Skills-First Program